Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Academia-industry collaborations to advance innovations & translational medicine in the cardiometabolic area.

Reference number
Coordinator Lunds universitet - Institutionen för experimentell medicinsk vetenskap, Lund
Funding from Vinnova SEK 3 819 143
Project duration October 2015 - March 2019
Status Completed

Purpose and goal

Projects were conducted as academia-industry collaborations for drug development in diabetes and cardiovascular disease. The aim and goal of the project were to together with the industry-partners investigate new, potential treatment options in this area. An important part of the project was to develop the applicant´s knowledge, contacts and skills in drug development, as well as to strengthen innovation power and industrial cooperation at Lund University. The aim was also to develop the applicant´s leadership ability.

Expected results and effects

The grant has been crucial for the researcher´s ability to further develop skills and knowledge within innovative drug development, and also to build an extended network in this area. In addition to the personal competence development, the grant has resulted in several positive effects including the dissemination of knowledge about drug development (for example via doctoral seminar) and increased industrial cooperation which includes contributions to the establishment of an Industry Research Center in diabetes ( with Pfizer as a partner.

Planned approach and implementation

The grant recipient made several longer stays at Pfizer, Cambridge, MA, USA, and one longer stay at Zealand Pharma in Denmark, and also had several virtual meetings for planning and follow-up. Recurring stays proved to be suitable for initiating new contacts and developing new project ideas. In addition, several educational activities were carried out, partly at Lund University (leadership) and at the companies (biosafety, intangible values, handling of sensitive / confidential information).

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 3 May 2019

Reference number 2015-01549

Page statistics